ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing

Many Gilead Sciences investors have lost faith in Trodelvy in HR-positive, HER2-negative breast cancer after disappointing data on tumor progression. But the antibody-drug conjugate has now made a surprise comeback with a life extension benefit that's greater than industry watchers’ expectations, reigniting blockbuster hopes.